BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 36496303)

  • 1. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
    Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
    Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
    J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study.
    Bilal M; Raza SEA; Azam A; Graham S; Ilyas M; Cree IA; Snead D; Minhas F; Rajpoot NM
    Lancet Digit Health; 2021 Dec; 3(12):e763-e772. PubMed ID: 34686474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
    Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
    Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
    León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
    J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
    Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
    J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
    Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
    Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial Cancer: Transitioning from Histology to Genomics.
    Mitric C; Bernardini MQ
    Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification of endometrial carcinoma, is it the new era of precision medicine?
    Bidzinski M; Danska-Bidzinska A; Rychlik A; Kypryjanczyk J; Pyzlak M; Piatek S
    Ginekol Pol; 2022; 93(2):163-167. PubMed ID: 35072255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
    Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
    Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Siegenthaler F; Lindemann K; Epstein E; Rau TT; Nastic D; Ghaderi M; Rydberg F; Mueller MD; Carlson J; Imboden S
    Gynecol Oncol; 2022 May; 165(2):230-238. PubMed ID: 35277281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
    Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
    Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
    Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials.
    Wakkerman FC; Wu J; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; Haverkort MAD; de Jong MA; Mens JWM; Wortman BG; Nout RA; Léon-Castillo A; Powell ME; Mileshkin LR; Katsaros D; Alfieri J; Leary A; Singh N; de Boer SM; Nijman HW; Smit VTHBM; Bosse T; Koelzer VH; Creutzberg CL; Horeweg N
    Lancet Oncol; 2024 Jun; 25(6):779-789. PubMed ID: 38701815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
    Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
    Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
    Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
    J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.
    Vermij L; Léon-Castillo A; Singh N; Powell ME; Edmondson RJ; Genestie C; Khaw P; Pyman J; McLachlin CM; Ghatage P; de Boer SM; Nijman HW; Smit VTHBM; Crosbie EJ; Leary A; Creutzberg CL; Horeweg N; Bosse T;
    Mod Pathol; 2022 Oct; 35(10):1475-1483. PubMed ID: 35752743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.